Rationale, Design and Baseline Characteristics of a Study to Evaluate Effects of Candesartan on Cardiovascular Events after Drug-eluting Stent Implantation in Patients with Ischemic Heart Disease

被引：1

作者：

Sakamoto, Tomohiro ^{[1
]}

Ogawa, Hisao ^{[2
]}

Nakao, Koichi ^{[1
]}

Koide, Shunichi ^{[3
]}

Yamamoto, Nobuyasu ^{[4
]}

Shimomura, Hideki ^{[5
]}

Matsumura, Toshiyuki ^{[6
]}

Oshima, Shuichi ^{[7
]}

Kikuta, Koichi ^{[8
]}

Oka, Hideki ^{[9
]}

Kimura, Kazuo ^{[10
]}

Matsui, Kunihiko ^{[11
]}

机构：

[1] Saiseikai Kumamoto Hosp, Div Cardiol, Cardiovasc Ctr, Kumamoto 8614193, Japan

[2] Kumamoto Univ, Grad Sch Med Sci, Dept Cardiovasc Med, Kumamoto, Japan

[3] Hlth Insurance Yatsushiro Gen Hosp, Div Cardiol, Yatsushiro, Japan

[4] Nobeoka Prefectural Hosp, Div Cardiol, Nobeoka, Japan

[5] Fukuoka Tokushukai Med Ctr, Dept Cardiovasc Med, Kasuga, Fukuoka, Japan

[6] Japan Labor Hlth & Welf Org Kumamoto Rosai Hosp, Div Cardiol, Yatsushiro, Japan

[7] Kumamoto City Hosp, Div Cardiol, Kumamoto, Japan

[8] Shinbeppu Hosp, Dept Cardiol, Beppu, Oita, Japan

[9] Hlth Insurance Hitoyoshi Gen Hosp, Div Cardiol, Hitoyoshi, Japan

[10] Yokohama City Univ, Med Ctr, Div Cardiol, Yokohama, Kanagawa 232, Japan

[11] Yamaguchi Univ, Dept Gen Med, Ube, Yamaguchi, Japan

来源：

JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS | 2013年 / 20卷 / 05期

关键词：

Angioplasty; Stent; Coronary artery disease; Angiotensin II; CORONARY-ARTERY-DISEASE; RANDOMIZED-TRIAL; UNCOATED STENTS; HYPERTENSION; MORBIDITY; INTERVENTION; VALSARTAN; MORTALITY; THERAPY; FAILURE;

D O I：

10.5551/jat.13870

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

Aim: Few multicenter studies have assessed the effects of angiotensin receptor blockers on cardiovascular events after drug-eluting stent implantation in patients with ischemic heart disease. Methods: An open-label multicenter randomized prospective study is in progress to evaluate the effects of candesartan on cardiovascular events in patients with ischemic heart disease after implantation of sirolimus- and/or paclitaxel-eluting stents. Results: A total of 1,145 patients were enrolled at 39 institutes in the Candesartan for prevention of Cardiovascular events after CYPHER or TAXUS Coronary stenting (4C trial). Patients were randomized into a group treated with candesartan (n=602) and a group treated with standard medical therapy without candesartan (n=543). The primary endpoint of the 4C trial is a composite of all-cause death, successful resuscitation after cardiopulmonary arrest and cardiovascular events including non-fatal myocardial infarction, unstable angina requiring emergent hospitalization, congestive heart failure requiring emergent hospitalization and cerebrovascular attacks. All patients will be followed-up for 36 months. Conclusions: The 4C trial will be the first multicenter study to elucidate the effects of candesartan after drug-eluting stent implantation and may provide new information to optimize medical therapy after percutaneous coronary interventions.

引用

页码：472 / 480

页数：9

共 24 条

[1] Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials [J].

Bangalore, Sripal ;

Kumar, Sunil ;

Wetterslev, Jorn ;

Messerli, Franz H. .

BMJ-BRITISH MEDICAL JOURNAL, 2011, 342

[2] Optimal medical therapy with or without PCI for stable coronary disease [J].

Boden, William E. ;

O'Rourke, Robert A. ;

Teo, Koon K. ;

Hartigan, Pamela M. ;

Maron, David J. ;

Kostuk, William J. ;

Knudtson, Merril ;

Dada, Marcin ;

Casperson, Paul ;

Harris, Crystal L. ;

Chaitman, Bernard R. ;

Shaw, Leslee ;

Gosselin, Gilbert ;

Nawaz, Shah ;

Title, Lawrence M. ;

Gau, Gerald ;

Blaustein, Alvin S. ;

Booth, David C. ;

Bates, Eric R. ;

Spertus, John A. ;

Berman, Daniel S. ;

Mancini, G. B. John ;

Weintraub, William S. ;

Boden, W. ;

O'Rourke, R. ;

Teo, K. ;

Hartigan, P. ;

Weintraub, W. ;

Maron, D. ;

Mancini, J. ;

Weintraub, W. ;

Boden, W. ;

O'Rourke, R. ;

Teo, K. ;

Hartigan, P. ;

Knudtson, M. ;

Maron, D. ;

Bates, E. ;

Blaustein, A. ;

Booth, D. ;

Carere, R. ;

Ellis, S. ;

Gosselin, G. ;

Gau, G. ;

Jacobs, A. ;

King, S., III ;

Kostuk, W. ;

Harris, C. ;

Spertus, J. ;

Peduzzi, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (15) :1503-1516

[3] Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].

Dahlöf, B ;

Devereux, RB ;

Kjeldsen, SE ;

Julius, S ;

Beevers, G ;

de Faire, U ;

Fyhrquist, F ;

Ibsen, H ;

Kristiansson, K ;

Lederballe-Pedersen, O ;

Lindholm, LH ;

Nieminen, MS ;

Omvik, P ;

Oparil, S ;

Wedel, H .

LANCET, 2002, 359 (9311) :995-1003

[4]

HOLM S, 1979, SCAND J STAT, V6, P65

[5]

*JAP SOC HYP GUID, 2004, GUID MAN HYP JSH 200

[6]

Japanese Society of Hypertension Guidelines Subcommittee for the Management of Hypertension, 2009, GUID MAN HYP JSH 200

[7] Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE) [J].

Kasanuki, Hiroshi ;

Hagiwara, Nobuhisa ;

Hosoda, Saichi ;

Sumiyoshi, Tetsuya ;

Honda, Takashi ;

Haze, Kazuo ;

Nagashima, Michitaka ;

Yamaguchi, Jun-ichi ;

Origasa, Hideki ;

Urashima, Mitsuyoshi ;

Ogawa, Hiroshi .

EUROPEAN HEART JOURNAL, 2009, 30 (10) :1203-1212

[8]

Kim S, 2000, PHARMACOL REV, V52, P11

[9] Anti-inflammatory and metabolic effects of candesartan in hypertensive patients [J].

Koh, KK ;

Quon, MJ ;

Han, SH ;

Chung, WJ ;

Lee, Y ;

Shin, EK .

INTERNATIONAL JOURNAL OF CARDIOLOGY, 2006, 108 (01) :96-100

[10] Effects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients with coronary artery disease [J].

Kondo, J ;

Sone, T ;

Tsuboi, H ;

Mukawa, H ;

Morishima, I ;

Uesugi, M ;

Kona, T ;

Kosaka, T ;

Yoshida, T ;

Numaguchi, Y ;

Matsui, H ;

Murohara, T ;

Okumura, K .

AMERICAN HEART JOURNAL, 2003, 146 (06)

← 1 2 3 →